Journal
DIABETES OBESITY & METABOLISM
Volume 12, Issue 12, Pages 1036-1047Publisher
WILEY
DOI: 10.1111/j.1463-1326.2010.01299.x
Keywords
beta cell; diabetes mellitus; PPAR-gamma agonist
Categories
Funding
- NIH [T32 HL079995, K08 DK080225, R03 DK 089147]
Ask authors/readers for more resources
The pathogenesis of type 2 diabetes mellitus involves both peripheral insulin resistance and dysfunctional insulin secretion from the pancreatic beta cell. Currently, there is intense research focus on delineating the etiologies of pancreatic beta cell dysfunction in type 2 diabetes. However, there remains an unmet clinical need to establish therapeutic guidelines and strategies that emphasize the preservation of pancreatic beta cell function in at-risk and affected individuals. Thiazolidinediones are orally active agents approved for use in type 2 diabetes and act as agonists of the nuclear hormone receptor PPAR-gamma. These drugs improve insulin sensitivity, but there is also a growing appreciation of PPAR-gamma actions within the beta cell. PPAR-gamma has been shown to regulate directly key beta cell genes involved in glucose sensing, insulin secretion and insulin gene transcription. Further, pharmacologic PPAR-gamma activation has been shown to protect against glucose-, lipid-, cytokine- and islet amyloid polypeptide (IAPP)-induced activation of numerous stress pathways. This article will review the mechanisms by which PPAR-gamma activation acts to maintain beta cell function and survival in type 2 diabetes mellitus and highlight some of the current controversies in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available